← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Max Biopharma, Inc.
Los Angeles, CA
$8,501,205
Total funding
9
Grants
Funding over time
peak $1.5M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,501,205 · 9
By mechanism
R44$7,342,166 · 4
R43$1,159,039 · 5
Investigators at Max Biopharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical Development of Oxy200 for the Treatment of Osteoporosis$975,009
R44 · FY2018 · AG
Preclinical Development of Oxy200 for the Treatment of Osteoporosis$975,009
R44 · FY2019 · AG
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis$896,990
R44 · FY2023 · DK
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis$889,701
R44 · FY2024 · DK
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion$855,153
R44 · FY2021 · AR
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion$852,387
R44 · FY2022 · AR
Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues$499,690
R44 · FY2017 · AG
Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues$498,960
R44 · FY2016 · AG
Synthesis of bone-selective osteogenic oxysterols$450,621
R44 · FY2017 · AR
Synthesis of bone-selective osteogenic oxysterols$448,646
R44 · FY2016 · AR
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH$320,724
R43 · FY2022 · HL
An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling$318,089
R43 · FY2022 · HL
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH$223,696
R43 · FY2020 · DK
Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analog$149,342
R43 · FY2014 · AR
Synthesis of bone-selective osteogenic oxysterols$147,188
R43 · FY2013 · AR